Androgen News and Research

RSS

Scientists track genetic pathway of prostate cancer in new approach to drug discovery

Tracking the genetic pathway of a disease offers a powerful, new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug currently marketed for congestive heart failure. Their findings are published in the current online issue of the Proceedings of the National Academy of Sciences.

14 Mar 2012

Exelixis initiates cabozantinib and abiraterone phase 1 combination trial in CRPC

Exelixis Inc. today announced the initiation of a phase 1 dose-finding trial of cabozantinib in combination with abiraterone in men with metastatic castration-resistant prostate cancer (CRPC) who have disease progression following treatment with up to two prior chemotherapy regimens.

5 Mar 2012

Ipsen total revenues increase 5.5% to €1,234.9M for the full year 2011

The Board of Directors of Ipsen, chaired by Marc de Garidel, met on 28 February 2012 to review the Group's results for 2011, published today.

29 Feb 2012

GTx fourth quarter net loss increases to $10.7 million

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2011.

21 Feb 2012

FDA prioritizes review of Ra-223 and MDV3100 for treating CRPC

The arsenal of prostate cancer treatments for men with advanced prostate cancer may soon be strengthened as the FDA prioritizes the review of both Ra-223 and MDV3100 for treating metastatic castration-resistant prostate cancer (CRPC). Based on positive, independent research of each drug, better survival rates and improved bone health for patients with late-stage prostate cancer may be within reach.

18 Feb 2012

Curcumin may block growth of castrate-resistant prostate tumors

Curcumin, an active component of the Indian curry spice turmeric, may help slow down tumor growth in castration-resistant prostate cancer patients on androgen deprivation therapy (ADT), a study from researchers at Jefferson's Kimmel Cancer Center suggests.

13 Feb 2012

Scientists study a botanical formula that kills aggressive prostate cancer tumors

Scientists at Indiana University, Methodist Research Institute study a botanical formula that kills aggressive prostate cancer tumors. Their findings, based on experiments in mice using a human prostate cancer tumor model, appear online in The International Journal of Oncology.

9 Feb 2012

Cancer Genomics now available online

Genome Research publishes online and in print today a special issue entitled, "Cancer Genomics," highlighting insights gained form cutting-edge genomic and epigenomic analyses of cancer.

2 Feb 2012

Study explains gender-related incidence of liver cancer

Men are four times more likely to develop liver cancer compared to women, a difference attributed to the sex hormones androgen and estrogen. Although this gender difference has been known for a long time, the molecular mechanisms by which estrogens prevent -- and androgens promote -- liver cancer remain unclear.

20 Jan 2012

Animal study confirms dramatic effects of natural formula against prostate cancer

New animal study confirms the dramatic effects of a natural formula against aggressive prostate cancer tumors. Researchers at the Methodist Research Institute at Indiana University conducted the study on mice, using a human prostate cancer xenograft model.

17 Jan 2012

Cabazitaxel with IMRT, androgen deprivation therapy may extend survival for prostate cancer patients

Jefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients.

13 Jan 2012

Hormone-blocking therapy for prostate cancer does not raise risk of heart attacks

Hormone-blocking therapy for prostate cancer doesn't raise the risk of fatal heart attacks - as some recent studies had suggested - according to a new report from Dana-Farber/Brigham and Women's Cancer Center.

7 Dec 2011

Herbicide atrazine linked to reproductive dysfunction

An international team of researchers has reviewed the evidence linking exposure to atrazine - an herbicide widely used in the U.S. and more than 60 other nations - to reproductive problems in animals. The team found consistent patterns of reproductive dysfunction in amphibians, fish, reptiles and mammals exposed to the chemical.

29 Nov 2011

Scientists design math model that could guide future prostate cancer treatments

Scientists have designed a first draft of a mathematical model that someday could guide treatment decisions for advanced prostate cancer, in part by helping doctors predict how individual patients will respond to therapy based on the biology of their tumors.

22 Nov 2011

Aurora kinase inhibitor may treat neuroendocrine prostate cancer

An international team of researchers led by clinicians at Weill Cornell Medical College have discovered a genetic Achilles' heel in an aggressive type of prostate cancer -- a vulnerability they say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.

17 Nov 2011

GTx third quarter net loss increases to $9.3 million

GTx, Inc. today reported financial results for the third quarter of 2011. The net loss for the quarter ended September 30, 2011 was $9.3 million compared with a net loss of $8.6 million for the quarter ended September 30, 2010, reflecting increased research and development costs in connection with the Company's Ostarine™ and Capesaris™ clinical development programs.

4 Nov 2011

New way to screen hirsutism among women

Examining the chin and upper and lower abdomen is a reliable, minimally invasive way to screen for excessive hair growth in women, a key indicator of too much male hormone, researchers report.

4 Nov 2011

Benefits of combined therapy for men with high-risk prostate cancer

Men with locally advanced or high-risk prostate cancer who receive combined radiation and hormone therapy live longer and are less likely to die from their disease, shows clinical research led by radiation oncologists at the Princess Margaret Hospital (PMH) Cancer Program, University Health Network.

3 Nov 2011

Small molecule selectively blocks gene activity regulated by thyroid hormone

A small molecule developed at St. Jude Children's Research Hospital advances progress toward more tailored drugs in research that also offers insight into the biology of thyroid hormone.

22 Oct 2011

AR gene has opposite effects on prostate and breast cancers

Researchers at Cleveland Clinic have discovered that a gene - known as an androgen receptor (AR) - is found in both prostate and breast cancers yet has opposite effects on these diseases.

18 Oct 2011